KRASG12V degradation upon dTAGV-1 administration (a) triggered the expansion and reduction of certain subtypes of tumor-infiltrating lymphoid (T and B cells) and myeloid cells (M1-like and M2-like macrophages and DCs), (b) promoted a shift of naive CD4+ and CD8+ T cells to effector/activated T cells and cytotoxic CD8+ T cells, and (c) elicited an increase in the expression of an antitumor cytotoxic gene signature. The gene discussed is CD4; the disease is neoplasm.